The DOI matches its Crossref record.
Amyloidosis—Where Are We Now and Where Are We Heading?
Abstract
Context. —Amyloidoses are disorders of diverse etiology in which deposits of abnormally folded proteins share distinctive staining properties and fibrillar ultrastructural appearance. Amyloidosis ultimately leads to destruction of tissues and progressive disease. With recent advances in the treatment of systemic amyloidoses the importance of an early diagnosis of amyloid, and a correct diagnosis of its type, has been realized. Objective. —To summarize current recommendations for the diagnosis of amyloidosis. Data Sources. —Presentation given at the 4th Annual Renal Pathology Society Satellite meeting in Istanbul based on discussions and recommendations formulated during an interactive diagnostic session held at the XIth International Symposium on Amyloidosis in Woods Hole, Massachusetts. Conclusions. —Congo red stain is currently the gold standard for amyloid detection and the goal is to detect amyloid early. Diagnosis of the amyloid type must be based on the identification of amyloid protein within the deposits and not solely by reliance on clinical or DNA studies. However, the latter are recommended for confirmation of the amyloid type based on evaluation of the protein in deposits. Immunohistochemistry must be performed and interpreted with caution and inconclusive results must be evaluated further using the more sophisticated methods available in referral centers. An adequate amount and quality of tissue must be available for amyloid diagnosis and typing with emphasis on the use of fresh tissue and greater use of abdominal fat biopsy. The development of new technologies underscores the need for regular review of recommendations and standards for the clinical diagnosis of amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Transthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Diagnosis of monoclonal gammopathy of renal significance
Bridoux, F., on behalf of the International Kidney and Monoclonal Gammopathy Research Group, Leung, N., Hutchison, C. A., Touchard, G., Sethi, S., Fermand, J.-P., Picken, M. M., Herrera, G. A., Kastritis, E., et al. (2015) · Kidney International · doi:10.1038/ki.2014.408 · Cited by 426
Self-citationDesport, E., Bridoux, F., Sirac, C., Delbes, S., Bender, S., Fernandez, B., Quellard, N., Lacombe, C., Goujon, J.-M., Lavergne, D., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-54 · Cited by 265
Snow, W. M., Dale, R., O’Brien-Moran, Z., Buist, R., Peirson, D., Martin, M., & Albensi, B. C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170136 · Cited by 29
Metadata
- Authors
- Picken, M. M.
- Venue
- Archives of Pathology & Laboratory Medicine
- Published
- 2010-04
- Volume
- 134
- Issue
- 4
- Pages
- 545-551
- ISSN
- 0003-9985 (ISSN-L)
- 1543-2165
- OpenAlex
- W4240830553
- Cited by
- 193
- References
- 0
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloidosis—Where Are We Now and Where Are We Heading? https://app.cochat.ai/papers/10.5858/134.4.545
- The paper
- Picken, M. M. (2010). Amyloidosis—Where Are We Now and Where Are We Heading? Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/134.4.545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.